肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

葛兰素史克GSK以51亿美元收购了生物制药公司Tesaro

2019-01-28 MedSci MedSci原创

GSKTesaroPARP抑制剂收购
关注

葛兰素史克已经完成了对以治疗肿瘤为重点的生物制药公司Tesaro的收购。两家公司于2018年12月3日宣布了此次交易，价值约51亿美元（40亿英镑）。GSK表示此次收购将大大加强其制药业务，并加快其肿瘤学管道的建设。

葛兰素史克已经完成了对以治疗肿瘤为重点的生物制药公司Tesaro的收购。两家公司于2018年12月3日宣布了此次交易，价值约51亿美元（40亿英镑）。GSK表示此次收购将大大加强其制药业务，并加快其肿瘤学管道的建设。

Tesaro的主要产品是Zejula（niraparib）是一种口服聚ADP核糖聚合酶（PARP）抑制剂，目前已在美国和欧洲被批准用于治疗对铂类化疗敏感，无论BRCA突变如何的复发性卵巢癌的成年患者。

GSK相信PARP抑制剂还将为多种癌症类型的治疗提供了治疗的可能性。除卵巢癌外，Zejula目前正在研究用于治疗肺癌、乳腺癌和前列腺癌，既可作为单药治疗，也可与其他药物联合使用。

GSK研发部首席科学官兼总裁Hal Barron博士说："收购Tesaro将大大增强我们的肿瘤学管道，获得的新的科学能力和专业知识可以提高我们癌症研究的速度和规模。"

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795649, encodeId=5a791e95649b8, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Jul 22 21:36:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315766, encodeId=c68a1315e666b, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387655, encodeId=6dee138e65578, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591526, encodeId=1b97159152686, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-07-22 huangshifeng

    #Tesaro#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1795649, encodeId=5a791e95649b8, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Jul 22 21:36:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315766, encodeId=c68a1315e666b, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387655, encodeId=6dee138e65578, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591526, encodeId=1b97159152686, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 sjq027

    #葛兰素史克#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1795649, encodeId=5a791e95649b8, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Jul 22 21:36:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315766, encodeId=c68a1315e666b, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387655, encodeId=6dee138e65578, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591526, encodeId=1b97159152686, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 柳叶一刀

    #生物制药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1795649, encodeId=5a791e95649b8, content=<a href='/topic/show?id=50ca1e28800' target=_blank style='color:#2F92EE;'>#Tesaro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17288, encryptionId=50ca1e28800, topicName=Tesaro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon Jul 22 21:36:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315766, encodeId=c68a1315e666b, content=<a href='/topic/show?id=6f0188218ee' target=_blank style='color:#2F92EE;'>#葛兰素史克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88218, encryptionId=6f0188218ee, topicName=葛兰素史克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387655, encodeId=6dee138e65578, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591526, encodeId=1b97159152686, content=<a href='/topic/show?id=12cb3239087' target=_blank style='color:#2F92EE;'>#制药公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32390, encryptionId=12cb3239087, topicName=制药公司)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36c517942572, createdName=xlwang2697, createdTime=Wed Jan 30 06:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 xlwang2697

    #制药公司#

    0

相关资讯

欧盟扩大了GSK / Innoviva哮喘吸入器的应用范围

欧盟委员会已批准对GSK/ Innoviva的Relvar Ellipta进行适应症更新，扩大了哮喘治疗的范围。该监管机构允许每日一次吸入皮质类固醇（ICS）/长效β2受体激动剂（LABA）联合用于哮喘已被充分控制的两种药物治疗的患者。该决定是根据一项非自发性肺功能研究的数据得出的，该研究显示，有充分控制的哮喘患者能够从每天两次的Seretide Accuhaler (氟替卡松丙酸酯/丙酸氟替卡松

GSK将牛皮癣/皮炎治疗药物Tapinarof出售给Dermavant

葛兰素史克（GlaxoSmithKline）以3.3亿美元的价格向Dermavant出售了具有牛皮癣和皮炎潜力的实验性疗法的所有权。Tapinarof是一种研究性治疗性芳香烃受体调节剂（TAMA），已在800多名人类受试者的多个I期和II期研究中的局部治疗中进行评价。在一项由安慰剂控制的全球阶段IIb剂量范围的研究中，56%的患者每天服用1%的药物，46％的患者在tapinarof 每日服用0.5

GSK宣布：恢复向医生支付费用

据彭博社报道，GSK宣布从10月份起将恢复向医生支付费用，包括讲课费、注册费、差旅费。GSK：合规政策未被效仿据微信公众号医药代表信息，葛兰素史克（GSK）认为近年来不向医生支付费用的做法降低了医生对其产品的了解，最终限制了患者获得新药和疫苗的途径，并且，这个做法没有被竞争对手仿效，这个政策只适用于某些产品和市场。此次做出恢复向HCPs（Health Care Practitioner，泛指医疗卫

香港九价宫颈癌疫苗断货一个半月：厂商受网络攻击致生产停摆

近日，中国香港多家医疗机构纷纷通知消费者，美国默沙东公司将在10月中旬至11月底期间暂停九价宫颈癌疫苗的供货，要求顾客更改注射时间或取消预约。10月17日上午，记者致电默沙东（亚洲）公司了解到，从10月13日起，已经开始暂停香港地区人类乳头瘤病毒（HPV）疫苗“佳达修9”的供应，而恢复供货的时间为12月1日。至于停货的原因，默沙东（亚洲）公司表示，在今年的6月28日，受到全球网络安全事件的波及，默

FDA专家质疑GSK的Nucala对慢性阻塞性肺病的疗效

美国监管顾问质疑葛兰素史克生物制剂Nucala治疗突然恶化的慢性阻塞性肺病（COPD）的有效性。

GSK提供二联药物的抗艾滋病数据 对Gilead展开全面进攻

葛兰素史克（GSK）一直尝试着通过联合两种药物方案，来战胜艾滋病毒（HIV）的标准三联疗法。在两项试验的详细数据中显示，GSK的Tivicay（度鲁特韦）和Epivir（拉米夫定）的联用，达到了与标准三联疗法一致的降低病毒荷载的疗效。